A phase I study of ADXS-504, a cancer type specific immunotherapy, for patients with biochemically recurrent prostate cancer. Background: The therapeutic benefit of pelvic lymph node dissection (PLND) ...
Fifteen-year outcomes of external radiation with or without 6 months of neoadjuvant deprivation therapy for intermediate risk prostate cancer. This is an ASCO Meeting Abstract from the 2025 ASCO ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果